Tofacitinib for Prurigo Nodularis: A Case Report

Peng, Changlan; Li, Chunxiao; Zhou, Yingying; Wang, Qiuyue; Xie, Ping; Li, Tianhao; Hao, Pingsheng

doi:10.2147/ccid.s354025

Cited by 12 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two clinical trials have been conducted to evaluate the efficacy of JAK inhibitors in prurigo nodularis ( 32 , 34 ). Several case reports showed that both oral and topical JAK1 inhibitors could be a good choice for treating refractory itch in patients with prurigo nodularis ( 35 , 36 ).…”

Section: Resultsmentioning

confidence: 99%

Itch and Janus Kinase Inhibitors

et al. 2023

View full text Add to dashboard Cite

Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a signalling mechanism that regulates gene expression through various cytokines. Janus kinase inhibitors, which have been tested and used for several autoimmune diseases, have also been shown to be effective for itch through clinical trials and case reports. Janus kinase inhibitors could be a good choice for pruritus in atopic dermatitis, psoriasis, and other diseases, such as prurigo nodularis and lichen planus, with rapid itch relief compared with conventional treatments. The most common adverse effects reported include nasopharyngitis, acne, and elevated blood creatine phosphokinase levels. Janus kinase inhibitors are currently prescribed with warnings about a potential increase in malignancies and cardiovascular diseases and usage in people of older ages. This review aims to provide knowledge about itch and the Janus kinase and signal transducer and activator of transcription pathway and to analyse the current evidence for itch relief by Janus kinase inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

Itch and Janus Kinase Inhibitors

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Clinical trials have found that all of the above drugs have good results in the treatment of moderate to severe AD [17,34] . However, there are only case reports of JAK inhibitors being effective in controlling the clinical symptoms of PN [33,35,36,37] . Therefore, more clinical RCTs around JAK inhibitors for PN need to be conducted to clarify their efficacy.…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

Dupilumab for Recurrent Prurigo Nodularis: A Case Report and Review of the Literature

2023

medsc

View full text Add to dashboard Cite

Prurigo nodularis (PN) is a chronic inflammatory skin disease that affects the quality of life of patients and is classified in the ICD-10 as a group of chronic lichen simplex and itchy skin diseases (ICD-10/L28) with an incidence of approximately 36.7-148.53 per 100,000 people. The pathogenesis of PN is closely related to type 2 inflammatory response. There are no standardized treatment guidelines for this disease, and traditional anti-pruritic treatment regimens often fail to control the vicious pruritic-scratch cycle in PN and have a poor safety profile. Traditional treatment options for PN include oral antihistamines, thalidomide, and topical hormones, calcium phosphatase inhibitors, and other treatments. However, traditional treatment options often suffer from poor pruritus control and high side effects. A patient with prurigo nodularis was admitted to our hospital who responded poorly to routine topical glucocorticoids and other drug therapies and relapsed after discharge from treatment. After readmission, the patient was successfully treated with dupilumab, a biological agent targeting interleukin-4/13. The patient's rash was significantly flattened, and the pruritus NRS score was significantly decreased. In this case, successful treatment of refractory PN with dupilumab could provide new ideas for treatment.

show abstract

“…14,15 For janus kinase inhibitors, we reported a case of an elderly CPG patient with complete relief of pruritus after 6 weeks of tofacitinib therapy, and the lesions did not recur after 5 months of follow-up after discontinuation of tofacitinib. 16 However, more real-world data are needed to demonstrate the effectiveness and safety of these emerging treatments for CPG in the future.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series

Luo

Wang

Lei

et al. 2022

CCID

Self Cite

View full text Add to dashboard Cite

Chronic prurigo (CPG) is a chronic inflammatory disease characterized by intense pruritus, and therapy is often challenging due to its unclear pathogenesis. Here, we report four patients with refractory CPG from different backgrounds who experienced failure of conventional therapy and were controlled with dupilumab, accompanied by a significant decrease in pruritus numerical rating scale, dermatology life quality index, and investigator global assessment, without adverse effects. Furthermore, dupilumab improved the condition of asthma in CPG patients along with an increase in asthma control test scores.

show abstract

Tofacitinib for Prurigo Nodularis: A Case Report

Cited by 12 publications

References 9 publications

Itch and Janus Kinase Inhibitors

Itch and Janus Kinase Inhibitors

Dupilumab for Recurrent Prurigo Nodularis: A Case Report and Review of the Literature

Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series

Contact Info

Product

Resources

About